Our aim was to investigate whether Asian ancestry increases the risk of thrombocytopenia-related dose-adjustment of an HER2-targeted antibody–drug conjugate independently of age, metastatic disease, specific drug, and prior dose adjustment for toxicity. This evidence concerns the gene ERBB2 and metastatic neoplasm.